Page 13 – The risk of replicating social bias in synthetic patient data – the need for human intelligence partnered with AI
Research Partnership of Inizio Advisory considers the benefits and drawbacks of AI, especially in terms of diversity and synthetic patients
Page 14 – Don’t settle for black box: why only explainable AI is built for scientific discovery
Abzu considers the benefits of AI and its different applications within the pharma industry
Page 16 – 2024: a tipping point for progress in rare diseases?
Alexion, AstraZeneca Rare Disease, explains why the EU must act in 2024 to tackle the health equity crisis that people living with rare diseases face every day
Page 18 – Paediatrics in the review of the EU General Pharmaceutical Legislation
Novartis considers the path to approval for paediatric medications
Page 20 – The impact of climate change on respiratory health
Chiesi reflects on the need to align environmental and health strategies and how to build a clearer picture of how climate change can impact respiratory health
Page 22 – Ageing populations and geographical health disparities in the UK
Pharmafocus considers how the UK’s ageing population impacts health trends, focusing on how a greater proportion of people’s lives are spent in ill health
Page 24 – Our Winter of Discontent: NHS strikes and missed targets
Pharmafocus considers the current state of the NHS amid strikes and ever-growing waiting lists, as well as the impact of infectious winter illnesses
Page 4-12 – News
PMGroup Worldwide Ltd
Group Managing Editor
Design & Layout
is published by:
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
Subscriptions & Data Management
Curwood CMS Tel: 01580 883840
is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).
All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.
©2024 Samedan Ltd, Pharmaceutical Publishers
The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.